Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 34 S3.3 | DOI: 10.1530/endoabs.34.S3.3

University Hospital Munich, Ludwig-Maximilians-University Munich, Munich, Germany.


As one of the oldest targets for molecular imaging and targeted radionuclide therapy, characterization of the sodium iodide symporter (NIS) as a novel reporter and suicide gene offers the possibility of NIS gene transfer in nonthyroidal tumors followed by diagnostic and therapeutic application of radioiodine. Our previous work has convincingly demonstrated the high efficacy of radionuclide therapy after tumor-selective NIS gene delivery. As logical consequence of our pioneer studies, the next crucial step towards clinical application of the promising NIS gene therapy concept is the evaluation of gene transfer methods that own the potential to achieve sufficient tumor-selective transgene expression levels after systemic application to be able to reach tumor metastases. For this purpose, the potential of novel polyplexes alone and for surface modification of replication-selective adenoviral vectors have been evaluated for systemic NIS gene delivery in addition to mesenchymal stem cells as gene delivery vehicles. Based on its dual function as reporter and therapy gene, NIS has been used in our studies for non-invasive imaging of vector biodistribution followed by monitoring of the therapy response after NIS-targeted radionuclide therapy.

Article tools

My recent searches

No recent searches.

Authors